MediciNova Appoints Geoffrey O'Brien as Vice President

MediciNova Appoints Geoffrey O'Brien as Vice President

SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a
biopharmaceutical company that is publicly traded on the NASDAQ Global Market
(Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:
4875), today announced the appointment of Geoffrey O'Brien, J.D./M.B.A. as
Vice President.

"I am very pleased to announce Geoff's appointment and welcome him to the
MediciNova executive management team," commented Yuichi Iwaki, M.D., Ph.D.,
MediciNova's President and Chief Executive Officer. "Geoff has added a
tremendous amount of value to MediciNova and has made substantial
contributions in a range of areas including business development, strategic
planning, clinical development, legal matters, patents, finance and
administration. In addition, Geoff has demonstrated strong leadership skills."

Mr. O'Brien has served as Senior Director, Business Development and Strategic
Planning for MediciNova since 2012 and was Director, Business Development from
2009-2012. Prior to joining MediciNova, Mr. O'Brien was an equity research
analyst covering pharmaceutical and biotechnology companies at UBS Securities,
Nomura Securities, and Punk, Ziegel, and was a Vice President from 2004-2008.
During his career as a senior equity research analyst on the sell side and buy
side, he focused on clinical, scientific, financial, strategic and competitive
analysis of development programs and marketed products. He used this analysis
to predict the future prospects of both development-stage and established
pharmaceutical and biotechnology companies. In addition, Mr. O'Brien executed
acquisitions and equity offerings as a health care investment banker at
Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. Prior to graduate
school, he worked on the successful development of a biotechnology product at
The Liposome Company. Mr. O'Brien received a B.S. in chemistry, cum laude,
from the University of Delaware and a J.D./M.B.A. from Vanderbilt University.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon
acquiring and developing novel, small-molecule therapeutics for the treatment
of diseases with unmet medical needs with a commercial focus on the U.S.
market. MediciNova's current strategy is to focus on its two prioritized
product candidates, MN-166 (ibudilast) for neurological disorders, and MN-221
for the treatment of acute exacerbations of asthma. MN-166 is being developed
in multiple indications, largely through investigator-sponsored trials and
outside funding. MediciNova is engaged in strategic partnering and consortium
funding discussions to support further development of both the MN-221 and
MN-166 programs. For more information on MediciNova, Inc., please visit

         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.